Larimar Therapeutics (LRMR) Non-Current Deferred Tax Liability (2022 - 2023)
Larimar Therapeutics' (LRMR) quarterly Non-Current Deferred Tax Liability came in at $768000.0 in Q4 2023, down 4.12% on a YoY basis from $801000.0 in Q4 2022, and down 4.12% quarter-over-quarter from $801000.0 in Q4 2022.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $768000.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Non-Current Deferred Tax Liability fell 4.12% year-over-year to $768000.0; the trailing twelve-month figure through Dec 2023 stood at $768000.0 (down 4.12% YoY), and the FY2023 full-year result was $768000.0, down 4.12% from the prior year.
- Non-Current Deferred Tax Liability fell to $768000.0 in Q4 2023 per LRMR's latest filing, from $801000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $801000.0 in Q4 2022 and bottomed at $768000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |